Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 60 Pages
|Stelara(克隆氏症)- 預測與市場分析 Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年01月31日||內容資訊: 英文 60 Pages||
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Janssen Biotech (a J&J subsidiary) is developing Stelara for the treatment of patients with moderate to severe CD (see the Disease Overview section for further discussion). Stelara is an IgG1 mAb that simultaneously targets the common p40 subunit of the IL-12/IL-23 cytokines, which are implicated in CD. According to J&J's October 15, 2013 product pipeline, Stelara is currently undergoing Phase III trials in CD patients who have failed anti-TNF therapies (UNITI-1 trial), as well as in those who have failed conventional corticosteroid and immunomodulator therapies (UNITI-2 trial).